PLAU

Across TCGA pan-cancer cohorts, PLAU mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PLAU data layer compared with 22 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PLAU mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PLAU expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where PLAU mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.261	0.492	<.001	115	view →
CCRCC	OS	Median	IV	0.948	0.167	.008	12	view →
GBM	DFS	Quartile	All	0.269	0.527	.025	6	view →
LUAD	OS	Median	All	0.790	1.000	.013	6	view →
HNSC	DFS	Quartile	IV	0.964	0.678	.019	3	view →
UCEC	DFS	Median	All	1.000	0.935	.020	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PLAU–PDAC (OS)

Open the PDAC breakdown →